408 related articles for article (PubMed ID: 25685861)
1. Pharmacovigilance Discussion Forum--The European Generic Medicines Association's 8th Annual Meeting (January 21, 2015--London, UK).
Lam S
Drugs Today (Barc); 2015 Jan; 51(1):89-92. PubMed ID: 25685861
[TBL] [Abstract][Full Text] [Related]
2. Strengthening and rationalizing pharmacovigilance in the EU: where is Europe heading to? A review of the new EU legislation on pharmacovigilance.
Borg JJ; Aislaitner G; Pirozynski M; Mifsud S
Drug Saf; 2011 Mar; 34(3):187-97. PubMed ID: 21332243
[TBL] [Abstract][Full Text] [Related]
3. Pharmacovigilance in Europe: Place of the Pharmacovigilance Risk Assessment Committee (PRAC) in organisation and decisional processes.
Laroche ML; Batz A; Géniaux H; Féchant C; Merle L; Maison P
Therapie; 2016 Apr; 71(2):161-9. PubMed ID: 27080834
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys.
Avery AJ; Anderson C; Bond CM; Fortnum H; Gifford A; Hannaford PC; Hazell L; Krska J; Lee AJ; McLernon DJ; Murphy E; Shakir S; Watson MC
Health Technol Assess; 2011 May; 15(20):1-234, iii-iv. PubMed ID: 21545758
[TBL] [Abstract][Full Text] [Related]
5. Signal detection activity on EudraVigilance data: analysis of the procedure and findings from an Italian Regional Centre for Pharmacovigilance.
Monaco L; Melis M; Biagi C; Donati M; Sapigni E; Vaccheri A; Motola D
Expert Opin Drug Saf; 2017 Mar; 16(3):271-275. PubMed ID: 28094583
[TBL] [Abstract][Full Text] [Related]
6. The reorganisation of European pharmacovigilance. Part 2. From spontaneous reports to agency reviews and decisions.
Prescrire Int; 2015 Feb; 24(157):50-4. PubMed ID: 25802924
[TBL] [Abstract][Full Text] [Related]
7. Establishing a Framework for the Use of Social Media in Pharmacovigilance in Europe.
Brosch S; de Ferran AM; Newbould V; Farkas D; Lengsavath M; Tregunno P
Drug Saf; 2019 Aug; 42(8):921-930. PubMed ID: 30929141
[TBL] [Abstract][Full Text] [Related]
8. Improving the Safety of Medicines in the European Union: From Signals to Action.
Potts J; Genov G; Segec A; Raine J; Straus S; Arlett P
Clin Pharmacol Ther; 2020 Mar; 107(3):521-529. PubMed ID: 31621897
[TBL] [Abstract][Full Text] [Related]
9. Geographical variation in reporting Interstitial Lung Disease as an adverse drug reaction: findings from an European Medicines Agency analysis of reports in EudraVigilance.
Pinheiro L; Blake K; Januskiene J; Yue QY; Arlett P
Pharmacoepidemiol Drug Saf; 2016 Jun; 25(6):705-12. PubMed ID: 27004571
[TBL] [Abstract][Full Text] [Related]
10. The Importance of Direct Patient Reporting of Adverse Drug Reactions in the Safety Monitoring Process.
Sienkiewicz K; Burzyńska M; Rydlewska-Liszkowska I; Sienkiewicz J; Gaszyńska E
Int J Environ Res Public Health; 2021 Dec; 19(1):. PubMed ID: 35010673
[TBL] [Abstract][Full Text] [Related]
11. EudraVigilance Medicines Safety Database: Publicly Accessible Data for Research and Public Health Protection.
Postigo R; Brosch S; Slattery J; van Haren A; Dogné JM; Kurz X; Candore G; Domergue F; Arlett P
Drug Saf; 2018 Jul; 41(7):665-675. PubMed ID: 29520645
[TBL] [Abstract][Full Text] [Related]
12. Harmonization of Pharmacovigilance Regulation in Brazil: Opportunities to Improve Risk Communication.
Varallo FR; Forgerini M; Herdeiro MT; de Carvalho Mastroianni P
Clin Ther; 2019 Mar; 41(3):598-603. PubMed ID: 30792075
[TBL] [Abstract][Full Text] [Related]
13. Patient Reporting in the EU: Analysis of EudraVigilance Data.
Banovac M; Candore G; Slattery J; Houÿez F; Haerry D; Genov G; Arlett P
Drug Saf; 2017 Jul; 40(7):629-645. PubMed ID: 28417320
[TBL] [Abstract][Full Text] [Related]
14. Monitoring the manufacturing and quality of medicines: a fundamental task of pharmacovigilance.
Sardella M; Belcher G; Lungu C; Ignoni T; Camisa M; Stenver DI; Porcelli P; D'Antuono M; Castiglione NG; Adams A; Furlan G; Grisoni I; Hall S; Boga L; Mancini V; Ciuca M; Chonzi D; Edwards B; Mangoni AA; Tuccori M; Prokofyeva E; De Gregorio F; Bertazzoli Grabinski Broglio M; van Leeuwen B; Kruger P; Rausch C; Le Louet H
Ther Adv Drug Saf; 2021; 12():20420986211038436. PubMed ID: 34394910
[TBL] [Abstract][Full Text] [Related]
15. Recommendations on the Use of Mobile Applications for the Collection and Communication of Pharmaceutical Product Safety Information: Lessons from IMI WEB-RADR.
Pierce CE; de Vries ST; Bodin-Parssinen S; Härmark L; Tregunno P; Lewis DJ; Maskell S; Van Eemeren R; Ptaszynska-Neophytou A; Newbould V; Dasgupta N; Wisniewski AFZ; Gama S; Mol PGM
Drug Saf; 2019 Apr; 42(4):477-489. PubMed ID: 30911975
[TBL] [Abstract][Full Text] [Related]
16. [The new pharmacovigilance legislation in practice].
Broekmans AW; Mol PG
Ned Tijdschr Geneeskd; 2014; 158():A7129. PubMed ID: 24846112
[TBL] [Abstract][Full Text] [Related]
17. Promoting and Protecting Public Health: How the European Union Pharmacovigilance System Works.
Santoro A; Genov G; Spooner A; Raine J; Arlett P
Drug Saf; 2017 Oct; 40(10):855-869. PubMed ID: 28735357
[TBL] [Abstract][Full Text] [Related]
18. Aims and approaches of Web-RADR: a consortium ensuring reliable ADR reporting via mobile devices and new insights from social media.
Ghosh R; Lewis D
Expert Opin Drug Saf; 2015; 14(12):1845-53. PubMed ID: 26436834
[TBL] [Abstract][Full Text] [Related]
19. Measuring the impact of the 2012 European pharmacovigilance legislation on additional risk minimization measures.
Francisca RDC; Zomerdijk IM; Sturkenboom MCJM; Straus SMJM
Expert Opin Drug Saf; 2018 Oct; 17(10):975-982. PubMed ID: 30107752
[TBL] [Abstract][Full Text] [Related]
20. Fighting trafficking of falsified and substandard medicinal products in Russia.
Fayzrakhmanov NF
Int J Risk Saf Med; 2015; 27 Suppl 1():S37-40. PubMed ID: 26639702
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
